Bayesian approaches to joint longitudinal and survival models accommodating both zero and nonzero cure fractions

The trade-offs between survival benefits and therapeutic adverse effects on quality of life (QOL) is always an important clinical issue for cancer and AIDS patients. The International Breast Cancer Study Group (IBCSG) conducted a large clinical trial, IBCSG Trial VI, to examine the duration and timing of adjuvant ther- apy for advanced breast cancer patients after the initial removal surgery. We present a novel joint model for longitudinal and survival data to evaluate the relationship between QOL and breast cancer progression, and also assess issues associated with different therapeutic procedures and baseline covariates. Multidimensional longi- tudinal QOL measurements are modeled in a hierarchical mixed effects model to account for psychological fluctuations and measurement errors, provide estimates for time points where QOL data are not available, and to explicitly allow for direct inferences about different dependence structures in the QOL data over time and over different QOL measures (indicators). A parametric survival model is also pro- posed for disease-free survival (DFS) to incorporate the underlying smooth QOL trajectories and prognostic factors. This survival model is attractive and capable of accommodating both zero and nonzero cure fractions. With advances in modern medicine, a positive cure fraction is often tenable for breast cancer patients since many are completely cured after surgery, and are no longer susceptible to relapse. A Bayesian paradigm is adopted to facilitate the estimation process and ease the computational complexity.

[1]  Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Forbes,et al.  Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer , 1996, The Lancet.

[3]  Joseph G. Ibrahim,et al.  BAYESIAN METHODS FOR JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA WITH APPLICATIONS TO CANCER VACCINE TRIALS , 2004 .

[4]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[5]  W. Gilks,et al.  Adaptive Rejection Metropolis Sampling Within Gibbs Sampling , 1995 .

[6]  Ming-Hui Chen,et al.  Monte Carlo Estimation of Bayesian Credible and HPD Intervals , 1999 .

[7]  Joseph G Ibrahim,et al.  Bayesian Approaches to Joint Cure‐Rate and Longitudinal Models with Applications to Cancer Vaccine Trials , 2003, Biometrics.

[8]  Jeremy M G Taylor,et al.  The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. , 2002, Biostatistics.

[9]  A. Gelfand,et al.  Efficient parametrizations for generalized linear mixed models, (with discussion). , 1996 .

[10]  A Yu Yakovlev,et al.  Stochastic Models of Tumor Latency and Their Biostatistical Applications , 1996 .

[11]  W. Gilks,et al.  Adaptive Rejection Sampling for Gibbs Sampling , 1992 .

[12]  S L Zeger,et al.  The Evaluation of Multiple Surrogate Endpoints , 2001, Biometrics.

[13]  Joseph G. Ibrahim,et al.  Bayesian Survival Analysis , 2004 .

[14]  Anastasios A. Tsiatis,et al.  Joint Modeling of Longitudinal and Time-to-Event Data : An Overview , 2004 .

[15]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[16]  Joseph Berkson,et al.  Survival Curve for Cancer Patients Following Treatment , 1952 .

[17]  Menggang Yu,et al.  JOINT LONGITUDINAL-SURVIVAL-CURE MODELS AND THEIR APPLICATION TO PROSTATE CANCER , 2004 .

[18]  Marie Davidian,et al.  An estimator for the proportional hazards model with multiple longitudinal covariates measured with error. , 2002, Biostatistics.